Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Ziupa, David ^a   Beck, Julia ^a   Franke, Gerlind ^a   Feliz, Stefanie Perez ^a   Hartmann, Maximilian ^a   Koren, Gideon ^b   Zehender, Manfred ^a   Bode, Christoph ^a   Brunner, Michael ^a   Odening, Katja E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ERYTHROMYCIN; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ACTION POTENTIAL DURATION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE; HEART PERFUSION; HEART RATE; HEART REPOLARIZATION; HEART RIGHT VENTRICLE; LONG QT SYNDROME 1; NONHUMAN; QT INTERVAL; SPATIAL ACTION POTENTIAL DURATION DISPERSION; TRANSGENIC RABBIT; TRIANGULATION; WILD TYPE; ACTION POTENTIAL; ANIMAL; DRUG EFFECTS; HEART; LONG QT SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; TRANSGENIC ANIMAL;

ORYCTOLAGUS CUNICULUS;

ACTION POTENTIALS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ERYTHROMYCIN; FEMALE; HEART; LONG QT SYNDROME; PIPERIDINES; PYRIDINES; RABBITS;

EID: 84907259426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107210     Document Type: Article

References (38)

1. Priori SG, Bloise R, Crotti L (2001) The long QT syndrome. Europace 3: 16-27.
2. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, et al. (2000) The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21: 1216-1231.
3. Molokhia M, Pathak A, Lapeyre-Mestre M, Caturla L, Montastruc JL, et al. (2008) Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol 66: 386-395.
4. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, et al. (2013) Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace.
5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
6. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
7. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, et al. (2000) Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11: 691-696.
8. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, et al. (2007) Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 4: 603-607.
9. Yang P, Kanki H, Drolet B, Yang T, Wei J, et al. (2002) Allelic variants in long- QT disease genes in patients with drug-associated torsades de pointes. Circulation 105: 1943-1948.
10. Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr, et al. (2005) Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2: 134-140.
11. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, et al. (2012) A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 5: 91-99.
12. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013-1022.
13. ICH Expert Working Group (2005) S7B: The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals, http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S7B/Step4/S7B-Guideline.pdf, Current Step 4 version dated 12 May 2005.
14. Kannankeril P, Roden DM, Darbar D (2010) Drug-induced long QT syndrome. Pharmacol Rev 62: 760-781.
15. Hondeghem LM (1994) Computer aided development of antiarrhythmic agents with class IIIa properties. J Cardiovasc Electrophysiol 5: 711-721.
16. Bentzen BH, Bahrke S, Wu K, Larsen AP, Odening KE, et al. (2011) Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits. J Cardiovasc Pharmacol 57: 223-230.
17. Biermann J, Wu K, Odening KE, Asbach S, Koren G, et al. (2010) Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo. Eur J Pharmacol 650: 309-316.
18. Odening KE, Jung BA, Lang CN, Cabrera Lozoya R, Ziupa D, et al. (2013) Spatial correlation of action potential duration and diastolic dysfunction in transgenic and drug-induced LQT2 rabbits. Heart Rhythm 10: 1533-1541.
19. Hondeghem LM, Carlsson L, Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
20. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, et al. (2002) Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 303: 218-225.
21. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, et al. (2006) No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol 149: 1039-1048.
22. Antzelevitch C (2008) Drug-induced spatial dispersion of repolarization. Cardiol J 15: 100-121.
23. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin JP (2006) A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 149: 845-860.
24. Guerard NC, Traebert M, Suter W, Dumotier BM (2008) Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods 58: 32-40.
25. Brunner M, Peng X, Liu GX, Ren XQ, Ziv O, et al. (2008) Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest 118: 2246-2259.
26. Nerbonne JM (2000) Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol 525 Pt 2: 285-298.
27. Odening KE, Hyder O, Chaves L, Schofield L, Brunner M, et al. (2008) Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. Am J Physiol Heart Circ Physiol 295: H2264-2272.
28. Odening KE, Kirk M, Brunner M, Ziv O, Lorvidhaya P, et al. (2010) Electrophysiological studies of transgenic long QT type 1 and type 2 rabbits reveal genotype-specific differences in ventricular refractoriness and His conduction. Am J Physiol Heart Circ Physiol 299: H643-655.
29. Roden DM (2006) Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 259: 59-69.
30. D'Alonzo AJ, Zhu JL, Darbenzio RB (1999) Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe. Eur J Pharmacol 369: 57-64.
31. Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW (2003) Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 254: 1-7.
32. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, et al. (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74: 230-241.
33. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, et al. (2007) In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 577: 222-232.
34. Shimizu W, Kurita T, Matsuo K, Suyama K, Aihara N, et al. (1998) Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 97: 1581-1588.
35. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, et al. (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351: 1089-1096.
36. Cheng J, Kamiya K, Liu W, Tsuji Y, Toyama J, et al. (1999) Heterogeneous distribution of the two components of delayed rectifier K+ current: a potential mechanism of the proarrhythmic effects of methanesulfonanilideclass III agents. Cardiovasc Res 43: 135-147.
37. Rampe D, Murawsky MK (1997) Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Naunyn Schmiedebergs Arch Pharmacol 355: 743-750.
38. Gravelin L, Ziv O, Hartmann K, Patel D, Schofield L, et al. (2012) Abstract: Transgenic LQT1 Animal Model Reveals Shifting Foci of EADs as Mechanism for Polymorphic VT. Heart Rhythm, Vol 9, No 5, May Supplement 2012, P03- 104.